PE20201278A1 - Una composicion farmaceutica para la anemia - Google Patents
Una composicion farmaceutica para la anemiaInfo
- Publication number
- PE20201278A1 PE20201278A1 PE2020000427A PE2020000427A PE20201278A1 PE 20201278 A1 PE20201278 A1 PE 20201278A1 PE 2020000427 A PE2020000427 A PE 2020000427A PE 2020000427 A PE2020000427 A PE 2020000427A PE 20201278 A1 PE20201278 A1 PE 20201278A1
- Authority
- PE
- Peru
- Prior art keywords
- guanosine
- composition
- anemia
- pharmaceutical composition
- lactoferrin
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 3
- 102000010445 Lactoferrin Human genes 0.000 abstract 3
- 108010063045 Lactoferrin Proteins 0.000 abstract 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 3
- 229940078795 lactoferrin Drugs 0.000 abstract 3
- 235000021242 lactoferrin Nutrition 0.000 abstract 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 abstract 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 abstract 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 abstract 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 abstract 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 abstract 2
- 235000013928 guanylic acid Nutrition 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a una composicion farmaceutica para la anemia, que comprenda una combinacion de: a) Lactoferrina (LF); y b) uno o mas nucleotidos de guanosina o una sal farmaceuticamente aceptable de estos. En donde una cantidad de lactoferrina oscila entre 5 y 90 % por peso de la composicion; donde el nucleotido de guanosina es seleccionado de monofosfato de guanosina (GMP), guanosina difosfato (GDP), guanosina trifosfato (GTP) o una combinacion de estos, y donde una cantidad de nucleotido de guanosina oscila entre 1 y 75% por peso de la composicion. Tambien se refiere diversas formulaciones, procesos para la preparacion de dicha composicion. Esta composicion/formulacion farmaceutica se usa en el tratamiento de la Anemia por Deficiencia de Hierro (IDA), Anemia de Inflamacion (AOI) y los trastornos neurodegenerativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821008809 | 2018-03-09 | ||
| PCT/IB2019/051706 WO2019171236A1 (en) | 2018-03-09 | 2019-03-04 | A pharmaceutical composition for anaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201278A1 true PE20201278A1 (es) | 2020-11-24 |
Family
ID=66397286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000427A PE20201278A1 (es) | 2018-03-09 | 2019-03-04 | Una composicion farmaceutica para la anemia |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12016906B2 (es) |
| EP (1) | EP3661373B1 (es) |
| AU (1) | AU2019232621B2 (es) |
| CA (1) | CA3073184C (es) |
| CO (1) | CO2020010193A2 (es) |
| DK (1) | DK3661373T3 (es) |
| EA (1) | EA202090276A1 (es) |
| ES (1) | ES2927216T3 (es) |
| HR (1) | HRP20221105T1 (es) |
| HU (1) | HUE059584T2 (es) |
| LT (1) | LT3661373T (es) |
| MA (1) | MA52154B1 (es) |
| MD (1) | MD3661373T2 (es) |
| MY (1) | MY183462A (es) |
| PE (1) | PE20201278A1 (es) |
| PH (1) | PH12019550263A1 (es) |
| PL (1) | PL3661373T3 (es) |
| PT (1) | PT3661373T (es) |
| RS (1) | RS63563B1 (es) |
| SG (1) | SG11202008732VA (es) |
| SI (1) | SI3661373T1 (es) |
| SM (1) | SMT202200364T1 (es) |
| UA (1) | UA123852C2 (es) |
| WO (1) | WO2019171236A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202020101861U1 (de) * | 2020-04-06 | 2020-04-16 | artgerecht GmbH | Eisen-enthaltende Formulierung, ernährungsphysiologische Zusammensetzung, welche diese enthält, und Verwendung derselben |
| IT202000012373A1 (it) * | 2020-05-26 | 2021-11-26 | Prosol S P A | Formulazione farmaceutica o di integratore alimentare per l’uso nel trattamento di disturbi dovuti alla carenza di ferro |
| IT202000022003A1 (it) * | 2020-09-18 | 2022-03-18 | Difass Int S R L | Composizioni comprendenti un sale minerale per uso orale |
| WO2022118274A1 (en) * | 2020-12-03 | 2022-06-09 | Neilos S.r.l. | Compositions for the use in the treatment and/or prevention of iron deficiency conditions or diseases |
| EP4440553A1 (en) * | 2021-12-03 | 2024-10-09 | DSM IP Assets B.V. | New delivery system for vitamin c |
| CN117180211A (zh) * | 2022-01-13 | 2023-12-08 | 上海医药集团青岛国风药业股份有限公司 | 一种多糖铁复合物的粉末直压片剂 |
| JP2025538134A (ja) * | 2022-11-03 | 2025-11-26 | ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー | 経口生体高分子送達系 |
| CN116530687A (zh) * | 2023-06-03 | 2023-08-04 | 重庆医科大学 | 一种含乳酸亚铁口服溶液及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022052A1 (en) | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
| CN1218647C (zh) * | 2003-04-03 | 2005-09-14 | 石家庄三鹿集团股份有限公司 | 新生婴儿奶粉 |
| WO2007022537A2 (en) | 2005-08-19 | 2007-02-22 | Agennix Incorporated | Use of lactoferrin as a chemokine and a chemotactic modulator |
| CN102481009A (zh) | 2009-08-13 | 2012-05-30 | 雀巢产品技术援助有限公司 | 包含外源性核苷酸的营养组合物 |
| EP3214951A1 (en) * | 2014-11-07 | 2017-09-13 | MJN U.S. Holdings, LLC | Nutritional compositions containing a prebiotic and lactoferrin and uses thereof |
| WO2018009647A1 (en) | 2016-07-06 | 2018-01-11 | Building Block Nutritionals, Llc | Nutritional formula |
| CN106578134A (zh) | 2016-12-31 | 2017-04-26 | 东北农业大学 | 一种预防感染性腹泻的婴儿配方奶粉 |
| CN107549612B (zh) | 2017-09-12 | 2021-01-12 | 东北农业大学 | 一种提高6-12个月龄婴儿免疫力的营养配方米粉 |
-
2019
- 2019-03-04 UA UAA202000922A patent/UA123852C2/uk unknown
- 2019-03-04 EP EP19721718.5A patent/EP3661373B1/en active Active
- 2019-03-04 DK DK19721718.5T patent/DK3661373T3/da active
- 2019-03-04 HR HRP20221105TT patent/HRP20221105T1/hr unknown
- 2019-03-04 MY MYPI2020001036A patent/MY183462A/en unknown
- 2019-03-04 MA MA52154A patent/MA52154B1/fr unknown
- 2019-03-04 SI SI201930331T patent/SI3661373T1/sl unknown
- 2019-03-04 RS RS20220855A patent/RS63563B1/sr unknown
- 2019-03-04 US US16/978,989 patent/US12016906B2/en active Active
- 2019-03-04 PE PE2020000427A patent/PE20201278A1/es unknown
- 2019-03-04 MD MDE20200629T patent/MD3661373T2/ro unknown
- 2019-03-04 SG SG11202008732VA patent/SG11202008732VA/en unknown
- 2019-03-04 AU AU2019232621A patent/AU2019232621B2/en active Active
- 2019-03-04 HU HUE19721718A patent/HUE059584T2/hu unknown
- 2019-03-04 PT PT197217185T patent/PT3661373T/pt unknown
- 2019-03-04 SM SM20220364T patent/SMT202200364T1/it unknown
- 2019-03-04 LT LTEPPCT/IB2019/051706T patent/LT3661373T/lt unknown
- 2019-03-04 CA CA3073184A patent/CA3073184C/en active Active
- 2019-03-04 EA EA202090276A patent/EA202090276A1/ru unknown
- 2019-03-04 ES ES19721718T patent/ES2927216T3/es active Active
- 2019-03-04 PL PL19721718.5T patent/PL3661373T3/pl unknown
- 2019-03-04 WO PCT/IB2019/051706 patent/WO2019171236A1/en not_active Ceased
- 2019-12-05 PH PH12019550263A patent/PH12019550263A1/en unknown
-
2020
- 2020-08-19 CO CONC2020/0010193A patent/CO2020010193A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3073184C (en) | 2021-11-16 |
| EP3661373A1 (en) | 2020-06-10 |
| AU2019232621B2 (en) | 2020-10-08 |
| CO2020010193A2 (es) | 2020-08-31 |
| UA123852C2 (uk) | 2021-06-09 |
| SG11202008732VA (en) | 2020-10-29 |
| PT3661373T (pt) | 2022-09-22 |
| HRP20221105T1 (hr) | 2022-11-25 |
| WO2019171236A1 (en) | 2019-09-12 |
| MD3661373T2 (ro) | 2022-11-30 |
| EP3661373B1 (en) | 2022-06-22 |
| ES2927216T3 (es) | 2022-11-03 |
| AU2019232621A1 (en) | 2020-03-12 |
| SMT202200364T1 (it) | 2022-11-18 |
| BR112020018319A2 (pt) | 2020-12-29 |
| LT3661373T (lt) | 2022-09-26 |
| MA52154A (fr) | 2020-06-10 |
| RS63563B1 (sr) | 2022-10-31 |
| CA3073184A1 (en) | 2019-09-12 |
| DK3661373T3 (da) | 2022-09-12 |
| US20200405822A1 (en) | 2020-12-31 |
| EA202090276A1 (ru) | 2020-11-16 |
| SI3661373T1 (sl) | 2022-10-28 |
| MA52154B1 (fr) | 2022-09-30 |
| US12016906B2 (en) | 2024-06-25 |
| PL3661373T3 (pl) | 2022-10-03 |
| MY183462A (en) | 2021-02-18 |
| HUE059584T2 (hu) | 2022-11-28 |
| PH12019550263A1 (en) | 2021-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201278A1 (es) | Una composicion farmaceutica para la anemia | |
| SV2018005771A (es) | Derivados de piridiniltriazol sustituidos con amida y usos de estos | |
| CO2021000537A2 (es) | Inhibidores de inflamasoma nlrp3 | |
| UY37725A (es) | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| DOP2018000153A (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridina-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d] pirimidina y los respectivos derivados de (1h-indazol-3-il) como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
| CO2017008403A2 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| MX2019008593A (es) | Azolopirimidina para el tratamiento de trastornos relacionados con el cancer. | |
| MX382221B (es) | Compuestos de fórmula iv para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| PH12018502606A1 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| UY37221A (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| SV2018005776A (es) | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| CO2021010931A2 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| MX2021009278A (es) | Nucleosidos antivirales y derivados de estos. |